• The P-I study involves assessing of FYB202 vs Stelara in patients evaluating the PK- safety- and tolerability while their dosing has been started last week
• Bioeq GmbH to sponsor the trial and will take care of study design and clinical operation FYB202 is developed in a joint venture between Aristo Pharma GmbH and Formycon AG
• FYB202 is a mAb targeting cytokines interleukin-12 and interleukin-23 used for the treatment of several different serious inflammatory diseases- such as moderate to severe psoriasis including UC- Crohn’s disease and psoriatic arthritis  

Click here to­ read full press release/ article | Ref: Formycon | Image: Behance